Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Free Cash Flow (2016 - 2025)

Rocket Pharmaceuticals' Free Cash Flow history spans 10 years, with the latest figure at -$34.5 million for Q4 2025.

  • For Q4 2025, Free Cash Flow rose 34.37% year-over-year to -$34.5 million; the TTM value through Dec 2025 reached -$190.0 million, up 11.86%, while the annual FY2025 figure was -$190.0 million, 11.86% up from the prior year.
  • Free Cash Flow for Q4 2025 was -$34.5 million at Rocket Pharmaceuticals, up from -$50.8 million in the prior quarter.
  • Across five years, Free Cash Flow topped out at -$24.6 million in Q1 2021 and bottomed at -$61.8 million in Q3 2023.
  • The 5-year median for Free Cash Flow is -$48.7 million (2024), against an average of -$46.6 million.
  • The largest annual shift saw Free Cash Flow crashed 81.14% in 2021 before it soared 42.42% in 2023.
  • A 5-year view of Free Cash Flow shows it stood at -$32.9 million in 2021, then crashed by 79.37% to -$59.0 million in 2022, then soared by 42.42% to -$34.0 million in 2023, then crashed by 54.59% to -$52.5 million in 2024, then skyrocketed by 34.37% to -$34.5 million in 2025.
  • Per Business Quant, the three most recent readings for RCKT's Free Cash Flow are -$34.5 million (Q4 2025), -$50.8 million (Q3 2025), and -$48.9 million (Q2 2025).